Related Experiment Video
Updated: Aug 31, 2025
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Financial toxicity in ovarian cancer
Allison L Swiecki-Sikora1, Amaranta D Craig2, Christina S Chu2
1Department of Obstetrics, Gynecology and Reproductive Sciences, Temple University Hospital, Philadelphia, Pennsylvania, USA allison.swiecki-sikora2@tuhs.temple.edu.
Abstract:
Ovarian cancer is the most costly and deadly of the gynecologic malignancies. Financial toxicity from out-of-pocket costs for direct care and medications as well as indirect costs from lost income is a growing challenge in oncology. The aim of this review is to focus on recent financial toxicity literature in the gynecologic oncology sphere and highlight specific issues and challenges regarding financial toxicity in ovarian cancer. Treatment options for ovarian cancer lead to variable costs for patients, and there are risk factors for high financial toxicity unique to gynecologic oncology patients. Identification and prompt intervention for those most at risk can help alleviate financial distress from ovarian cancer care.
